How to Transfer CAR-T Cell Therapy Technology: A Step-by-Step Guide

Define the exact product and rights before anything else. "CAR-T technology" can mean very different packages.

• Transfer tacit knowledge, not only documents. Most failures trace back to what was never written down.
• Fix the regulatory strategy before freezing the facility design.
• Analytical transfer, especially potency, is usually the critical path, not the cleanroom.
• Minimize changes between the sending and receiving process in the first implementation. Optimize later under change control.
• Manufacturing is not a treatment program. Clinical delivery must be built in parallel.

Regulators treat the modified cells as the gene therapy product. FDA's January 2024 final guidance defines CAR T cell products as human gene therapy products and gives recommendations on CMC, pharmacology and toxicology, clinical study design and analytical comparability. It also discusses managing manufacturing changes, comparability across the product lifecycle, and single-site versus multi-site manufacturing, and it notes that much of it applies to CAR-NK and TCR-modified cells. That makes it a useful technical reference even when your regulator is not FDA.

In India, cell and gene therapy products are regulated as drugs under the New Drugs and Clinical Trials (NDCT) Rules, 2019, and are treated as new drugs. Step 5 below covers recent changes.

Each step is covered in detail below.

Write down the product profile before talking to any technology owner. At minimum:

• Target antigen and indication (for example CD19, CD20, CD22, BCMA, GPRC5D, or dual-target constructs)
• Autologous or allogeneic platform
• CAR architecture (binder format, hinge and transmembrane region, costimulatory domain)
• Gene delivery method (commonly lentiviral or gamma-retroviral vectors, with non-viral approaches still emerging)
• Fresh or cryopreserved final product
• Clinical maturity and regulatory status in the originating country
• Territory, field of use and exclusivity sought

Be explicit about maturity. A CD19 or BCMA product with approved counterparts and substantial clinical history carries a very different risk profile from a solid tumor construct such as Claudin 18.2, GPC3 or GD2, which remains investigational. Valuation, infrastructure and timeline all follow from this distinction.

Scientific. Look beyond headline response rates. Review durability, cytokine release syndrome and neurotoxicity rates, cytopenias, infection data, antigen escape patterns and available long-term follow-up. Check whether the cohorts resemble the patients in your market, since disease biology, prior therapy and baseline organ function affect outcomes.

Manufacturing. This is where many deals are won or lost. Ask for:

• Manufacturing success and out-of-specification rates by batch, not only for released lots
• Variability in starting material (leukapheresis quality, T cell fitness, prior treatment effects)
• Dependence on proprietary consumables, media or closed-system platforms
• Vector supply: who makes the vector, at what titer and scale, and who controls it
• Process duration, expansion method and scale-out strategy

Regulatory. Establish whether the product is approved anywhere, what CMC documentation exists, what inspections have occurred, and whether the data package can support a filing in your jurisdiction. Registration of a trial is not approval, so confirm the actual status.

Intellectual property. Map patents and know-how covering the binder, CAR sequence, signaling domains, vector, process and assays, country by country. A strong licence on weak territorial coverage is a poor asset.

Commercial terms and technical scope should be negotiated together. The agreement should define:

• Territory and field: specific countries, indications and whether manufacturing, import, distribution and sublicensing are included
• Financial structure: combinations of upfront fees, milestones, royalties, per-patient or per-batch payments, minimum commitments, equity or profit-sharing
• Deliverables: the exact transfer package, number of training visits, technical support duration, and support for regulatory questions
• Supply terms: vector and critical reagent supply, pricing, continuity and step-in rights
• Improvements: ownership and licensing of process improvements made by either side
• Quality agreement: responsibilities for change notification, deviations, recalls and data sharing

A vague transfer scope is the most common source of later disputes, because tacit knowledge was assumed to be included but never listed.

Compare the sending site and the intended receiving operation in writing. The output is a Technology Transfer Gap Assessment that drives the project plan.

Exact equipment replication is not always possible, but every difference needs a documented risk assessment and a plan to show that it does not affect product quality.

Building first and asking questions later is the most expensive mistake in this field. Regulatory strategy should determine what authorizations are needed for import, research use, manufacture, clinical trials and commercial supply, and what GMP standard applies at each stage.

Typical reference frameworks. Depending on the market, developers commonly benchmark against FDA's CAR-T guidance, the EU's GMP requirements for advanced therapy medicinal products (EudraLex Volume 4, Part IV), and PIC/S and WHO GMP principles, alongside the national regulator's own rules.

India: what a developer should know now

• Under the NDCT Rules, cell and gene therapy products are new drugs, and the pathway includes clinical trial permission followed by marketing authorization after expert committee review. A CDSCO presentation also indicates that import of a cell bank requires approval from the institutional biosafety committee (IBSC) and the Review Committee on Genetic Manipulation (RCGM).
• The 2019 National Guidelines for Gene Therapy Product Development and Clinical Trials explicitly address ex vivo gene transfer approaches such as CAR-T and CAR-NK. Check the current text of the guideline for how RCGM, the Gene Therapy Advisory and Evaluation Committee (GTAEC) and CDSCO divide responsibilities for your specific product.
• A recent change matters for licensing. The Drugs (Eighth Amendment) Rules, 2026 were notified in mid-2026 and extend provisions and licence forms that previously referred to r-DNA derived drugs to also cover cell or stem cell derived products, gene therapeutic products and xenografts. Reporting describes this as bringing these products into the Centrally Licence Approving Authority (CLAA) framework, which involves joint supervision by central and state regulators. Developers should have regulatory counsel confirm what this means for manufacturing licence applications.
• India now has precedent. CDSCO approved NexCAR19, India's first CAR-T therapy, in October 2023; it was developed by ImmunoACT, an IIT Bombay incubated company, through work involving Tata Memorial Centre. A second CAR-T therapy was approved in January 2025. The regulator has therefore reviewed locally manufactured CAR-T dossiers, which lowers regulatory novelty risk, though it does not make a new product's path predictable.

Engage the regulator early. A scientific advice or pre-submission discussion on your manufacturing model can save a facility redesign.

Documents carry the explicit knowledge. A complete package includes product description and CQAs, process maps, master batch records, critical process parameters and ranges, in-process controls, material specifications, deviation and CAPA history, historical process performance, and the full analytical package.

The tacit knowledge is what documents miss: how cells look at day 3 when a batch is trending well, how long a bead removal step really takes before viability drops, which media lot behaved differently, what operators do when expansion lags. Capture it through side-by-side observation, recorded walkthroughs, structured interviews with senior operators, and a deviation review focused on "what almost went wrong."

This follows the principle in ICH Q10, which frames technology transfer as moving product and process knowledge to support the control strategy, validation approach and continual improvement.

Three models dominate:

Design inputs include the process (open versus closed steps, which sets the required background classification), batch volume and scale-out plan, separation of vector handling from cell processing where relevant, biosafety requirements for viral vectors, cryogenic capacity, and environmental monitoring. Automated closed-system platforms can reduce the cleanroom burden and operator variability, but they are a process change if the original process was run differently. Treat them as such in your comparability plan.

The receiving laboratory must show it can measure product quality as the sender does. Typical release and characterization attributes include identity and cell composition (for example CD3 positive fraction by flow cytometry), viability and cell count, transduction efficiency or CAR expression, vector copy number, sterility, mycoplasma and endotoxin, residual process impurities, and tests for replication-competent virus where a viral vector is used. Specific assays and limits depend on the product and the regulator.

Potency deserves special attention. It is often the hardest assay to transfer because cell-based assays are variable and depend on target cell lines, effector to target ratios, readout platforms and analyst technique. In December 2023 FDA issued a draft guidance, "Potency Assurance for Cellular and Gene Therapy Products," recommending a science and risk based approach to assuring potency across the product lifecycle, including testing required for lot release for licensed products. When finalized, it will supersede the January 2011 potency guidance. Treat it as a statement of regulatory direction, and check its current status before citing it in a dossier.

A sound analytical transfer plan includes a transfer protocol with pre-defined acceptance criteria, comparative testing of the same retained samples at both sites, shared reference materials, analyst qualification, and a plan for assay lifecycle management.

Training in two directions works best. Receiving personnel observe and participate in production and QC at the originating site, and then the sender's experts support the first runs at the receiving site. Use competency-based qualification: theory, observation, supervised practice, assessment, sign-off and periodic requalification. Aseptic technique should be verified through media fill or equivalent aseptic process simulation under your applicable GMP framework. Attendance records are not evidence of competence.

The aim is to demonstrate that the receiving site can run the transferred process within the intended control strategy. Typical activities:

• Facility, utility and equipment qualification
• Environmental monitoring baseline
• Analytical method transfer and qualification
• Engineering or demonstration runs, often using healthy donor material
• Transfer batches evaluated against pre-defined acceptance criteria
• Comparability assessment between sending and receiving site product

A practical principle: change as little as possible at first. Switching equipment, media, vector lot and operating parameters at once makes any difference impossible to attribute. FDA's CAR-T guidance includes recommendations on analytical comparability studies, so design your comparability protocol around product-specific CQAs, a side-by-side data set and pre-specified acceptance ranges, and agree on the approach with the regulator when the change is material. The level of validation expected scales with development stage, so confirm expectations for early-phase versus commercial supply with your regulator.

A CAR-T program needs functioning clinical delivery, not only a product. The hospital needs systems for patient selection and eligibility review, leukapheresis, chain of identity and chain of custody from collection to infusion, bridging therapy decisions, lymphodepletion, product receipt and thaw procedures, infusion, monitoring and management of cytokine release syndrome and neurotoxicity, ICU access, and long-term follow-up.

Staffing spans hematology and oncology, transplant and cell therapy physicians, neurology, critical care, infectious disease, pharmacy, transfusion medicine, nursing and laboratory teams. Long-term follow-up is also a regulatory expectation for gene-modified cell products in major jurisdictions, and safety communications on secondary malignancies in approved CAR-T products reinforce why registries and follow-up systems should be designed from the start.

After the process is established to the level required for the stage, proceed with the regulatory path: manufacturing documentation, nonclinical package, protocols, ethics approval, trial authorization, safety reporting and eventually marketing authorization.

Two cautions. First, changes in CMC information during clinical development need documented scientific justification and regulatory notification where required, so change control must exist from day one. Second, transfer does not end with the first successful batch. Establish trending of yield, viability and potency, deviation and CAPA review, supplier monitoring, equipment maintenance, periodic review and a process for controlled improvement. ICH Q10 places technology transfer inside this broader lifecycle quality system.

1. Selecting on clinical data alone. Strong response rates do not mean the process is robust or scalable.
2. Incomplete know-how transfer. A stack of SOPs is not a transfer.
3. Facility before regulatory strategy. This leads to costly redesign.
4. Too many simultaneous changes. Comparability becomes impossible to interpret.
5. Underestimating analytics. Potency and characterization become the bottleneck.
6. Single-source dependency. One imported vector or reagent supplier can halt production.
7. No clinical readiness. The hospital cannot safely administer and monitor the product.
8. Weak governance. Scientists, engineers, regulators, lawyers and clinicians drift apart without a central program structure.

Run the project as a formal program with a joint steering committee and separate workstreams for CMC and manufacturing, quality and analytics, facility and engineering, regulatory affairs, clinical development, supply chain, IP and commercial, and project management. Each workstream needs an owner, deliverables, acceptance criteria, a risk register and an escalation route.

There is no reliable universal timeline. Duration depends on technology maturity, the existing GMP infrastructure, the regulatory pathway, equipment lead times, workforce readiness, the number of process differences between sites, and clinical development requirements. A group with an operating cell therapy GMP suite is in a different position from one starting from a greenfield site. Plan it as a multiyear program, and treat any quoted timeline as an estimate until due diligence is complete.

For many hospital groups and pharma companies in emerging markets, a licensed platform is a practical entry point, with in-house development added later as capability matures.

Once an organization has aseptic cell processing, vector handling, flow-based characterization, cryogenic logistics, QC and QA systems and clinical cell therapy operations, the platform can support further programs subject to separate technology rights and authorization: additional CAR-T targets, dual-target constructs, CAR-NK, TCR-T and other engineered cell products. The goal is a sustainable regional capability, not one imported process.

The hardest parts of CAR-T technology transfer are usually the least visible: tacit process knowledge, potency assay performance, comparability design and clinical readiness. Organizations that scope these early, keep process changes minimal during first implementation, and run the effort as one governed program are better placed to reach reproducible, inspectable manufacturing. Rather than asking whether a technology can be moved, ask whether the receiving organization can operate it independently, to a regulator's satisfaction, for years.

VectorGene Biotech Limited supports hospitals, pharmaceutical manufacturers, biotechnology companies and research institutions in evaluating CAR-T technology transfer, licensing and localisation opportunities, including technology sourcing, due diligence, manufacturing and regulatory planning. Technology availability and licensing rights are partner-specific and subject to confirmation.

Contact: partnerships@vectorgene.hk | CAR-T and cell therapy technology transfer

Disclaimer: This article is a strategic overview, not a manufacturing protocol, regulatory or legal opinion. Requirements vary by product and jurisdiction. Reviewed 29 October 2026.

1. FDA CBER. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, Final Guidance, January 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products
2. FDA CBER. Potency Assurance for Cellular and Gene Therapy Products, Draft Guidance, December 2023. https://www.fda.gov/media/175132/download
3. ICH Q10, Pharmaceutical Quality System (technology transfer activities).
4. WHO. Guidelines on transfer of technology in pharmaceutical manufacturing (TRS 961, Annex 7).
5. European Commission. EudraLex Volume 4, Part IV: GMP for Advanced Therapy Medicinal Products.
6. India: New Drugs and Clinical Trials Rules, 2019 (CDSCO).
7. ICMR, DBT, CDSCO. National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019.
8. Ministry of Health and Family Welfare. Drugs (Eighth Amendment) Rules, 2026 (Gazette of India, June/July 2026).
9. BioSpectrum India. Cell and Gene Therapy: How Close Is India to the Frontier? (NexCAR19 and January 2025 approval). https://biospectrumindia.com/views/96/28553/cell-and-gene-therapy-how-close-is-india-to-the-frontier.html